Superior Hypogastric Nerve Block for pain prevention after Minimally invasive gynecology surgeries
Not Applicable
Completed
- Conditions
- Health Condition 1: N859- Noninflammatory disorder of uterus, unspecified
- Registration Number
- CTRI/2023/04/051909
- Lead Sponsor
- AIIMS Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 64
Inclusion Criteria
1.Patients undergoing minimally invasive gynecology surgeries like total laparoscopic or robotic hysterectomy and myomectomy for benign conditions and for premalignant lesions.
2.Age above 18 years
3.Patients consenting for the study.
Exclusion Criteria
1.Extensive Endometriosis.
2.Known malignancy
3.Allergy to Ropivacaine, NSAIDS, opioids.
4.Long term opioid use
5.Patients not giving consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in the severity of pain using VAS Score after performing minimally invasive gynecological surgeries in the subjects that received Superior hypogastric nerve block using Ropivacaine 10 mL (0.75%) and those who do not received it.Timepoint: 1 hour, 2 hour, 6 hour, 12 hour, and 24 hour after extubation
- Secondary Outcome Measures
Name Time Method eed of additional analgesicTimepoint: 24hours of surgery